Alnylam Pharmaceuticals
ALNY
#619
Rank
NZ$56.63 B
Marketcap
$437.49
Share price
3.74%
Change (1 day)
78.60%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

Earnings for Alnylam Pharmaceuticals (ALNY)

Earnings in 2024 (TTM): -NZ$0.41 Billion

According to Alnylam Pharmaceuticals 's latest financial reports the company's current earnings are NZ$2.24 Billion. , an increase over its 2023 earnings that were of -NZ$0.54 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Alnylam Pharmaceuticals from 2003 to 2024

Annual earnings

Year Earnings Change
2024 -NZ$0.41 Billion-24.59%
2023 -NZ$0.54 Billion-67.84%
2022 -NZ$1.68 Billion36.93%
2021 -NZ$1.23 Billion-8.04%
2020 -NZ$1.34 Billion-15.66%
2019 -NZ$1.58 Billion12.23%
2018 -NZ$1.41 Billion62.91%
2017 -NZ$0.87 Billion17.78%
2016 -NZ$0.74 Billion43.44%
2015 -NZ$0.52 Billion60.69%
2014 -NZ$0.32 Billion98.2%
2013 -NZ$0.17 Billion
2011 -NZ$94.63 Million27.48%
2010 -NZ$74.23 Million-10.92%
2009 -NZ$83.33 Million95.77%
2008 -NZ$42.57 Million
2006 -NZ$68.19 Million-9.13%
2005 -NZ$75.05 Million34.74%
2004 -NZ$55.7 Million36.79%
2003 -NZ$40.72 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-NZ$1.04 Billion 154.87%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$8.25 B-2,129.54%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$0.45 B-210.72%๐Ÿ‡บ๐Ÿ‡ธ USA
-NZ$17.89 Million-95.60%๐Ÿ‡บ๐Ÿ‡ธ USA
-NZ$71.42 Million-82.43%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$23.54 B-5,891.51%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
NZ$13.70 B-3,472.17%๐Ÿ‡ซ๐Ÿ‡ท France
-NZ$0.49 Billion 19.74%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel